Company news

Ocugen, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024

May 19, 2024

Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy

May 14, 2024

Ocugen Provides Business Update with First Quarter 2024 Financial Results

May 13, 2024

Ocugen to Present at May 2024 Investor Conferences

May 9, 2024

Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock

May 9, 2024

Ocugen to Host Conference Call on Tuesday, May 14 at 8: 30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results

May 2, 2024

Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress

May 1, 2024

Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024

April 28, 2024

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting

April 25, 2024

Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy

April 18, 2024

Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets

April 11, 2024

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication

April 9, 2024

Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication

April 7, 2024

Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy

April 4, 2024

Ocugen Provides Business Update with Certain Financials for the Year Ending 2023

April 1, 2024

Ocugen to Host Conference Call on Tuesday, April 2 at 8: 30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023

March 31, 2024

Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease

March 31, 2024

Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer

March 17, 2024

Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410

March 12, 2024

Ocugen to Present at Investing in Cures Summit

March 5, 2024

Ocugen Clinical Showcase Webcast Now Available

February 27, 2024

Ocugen Chairman and CEO to present at Abu Dhabi Family Office Summit

February 25, 2024

Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST

February 21, 2024

Ocugen to Present at 2024 BIO CEO & Investor Conference

February 20, 2024

Ocugen to Host Clinical Showcase in New York City on Wednesday, February 21, 2024

February 13, 2024

Ocugen to Present at Pharma Market Research Conference

January 30, 2024

Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board

January 15, 2024

Ocugen Gains FDA Alignment on Key Aspects of OCU400—Modifier Gene Therapy—Pivotal Phase 3 Study Design

December 20, 2023

Ocugen Announces OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Retinitis Pigmentosa Associated with RHO Mutations

December 18, 2023

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

December 12, 2023

Ocugen CEO to Present at NobleCon19 – Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference

November 28, 2023

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST—Modifier Gene Therapy—for Stargardt Disease

November 9, 2023

Ocugen Provides Business Update with Third Quarter 2023 Financial Results

November 8, 2023

Ocugen CSO to Participate in 4th Annual Dry AMD Therapeutic Development Summit

November 6, 2023

Ocugen to Host Conference Call on Thursday, November 9 at 8: 30 A.M. ET to Discuss Business Updates and Third Quarter 2023 Financial Results

November 1, 2023

Ocugen Mucosal Vaccine Candidate OCU500 Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials

October 9, 2023

Ocugen to Present at the 2023 Cell & Gene Meeting on the Mesa

October 3, 2023

Ocugen CSO to Participate in 4th Annual Gene Therapy for Ophthalmic Disorders Conference

September 28, 2023

Ocugen to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference

September 26, 2023

Ocugen, Inc. Announces Connie Collingsworth Joins Business Advisory Board

September 20, 2023

Ocugen to Participate in Panel at Cantor Fitzgerald Global Healthcare Conference 2023

September 19, 2023

Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)

September 12, 2023

Ocugen to Host Virtual Investor & Analyst Event on September 13, 2023

September 11, 2023

Ocugen Provides Business Update with Second Quarter 2023 Financial Results

August 20, 2023

Ocugen to Host Conference Call on Tuesday, August 22 at 8: 30 A.M. ET to Discuss Business Updates and Second Quarter 2023 Financial Results

August 17, 2023

Ocugen CEO & CSO to Present at 41st Annual AAPI Convention and Scientific Assembly

June 29, 2023

Ocugen, Inc. Announces Adjournment of Annual Meeting of Shareholders

June 8, 2023

Ocugen, Inc. Announces Business Advisory Board

June 4, 2023

Ocugen, Inc. Announces Pricing of $16.5 Million Public Offering of Common Stock

May 23, 2023

Ocugen to Present at BIO International Convention 2023

May 22, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 23 calls. Every call is listed under its year.

Decks

The 5 newest of 75 decks. Every deck is listed under its year.